Drugs / Pathogen-specific aAPC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04299724 | Jun 2026 → Dec 2029 expected | — | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pathogen-specific aAPC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04299724 ↗ |
| Action | Activate | “to activate T cells” NCT04299724 ↗ |
| Modality | Cell therapy | “The Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes, to the artificial antigen presenting cells (aAPCs).” NCT04299724 ↗ |
| Route | Subcutaneous | “via subcutaneous injections” NCT04299724 ↗ |